Prevention and Pharmacovigilance: What Should We Do, What Can We Do?

ISSN： 0114-5916

Source： Drug Safety, Vol.35, Iss.2, 2012-02, pp. : 87-90

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuropsychiatric Adverse Effects of Mefloquine: What Do We Know and What Should We Do?

By Nosten F.

CNS Drugs, Vol. 11, Iss. 1, 1999-01 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite

Dilemmas about the toxicological consequences of metal-on-metal hip prostheses - What we do and do not know, and what we should do?

By Brent Jeffrey

Clinical Toxicology, Vol. 51, Iss. 4, 2013-05 ,pp. : 195-198

Informa Healthcare

Access to resources Recommend Favorite

The diabetic heart - what is to blame and what can we do?

Inpharma, Vol. 1, Iss. 1302, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Thrombolytic Therapy for Acute Ischaemic Stroke: What Can We Do to Improve Outcomes?

By Demchuk Andrew M.

Drugs, Vol. 72, Iss. 14, 2012-10 ,pp. : 1833-1845

Adis International

Access to resources Recommend Favorite

Today's Challenges in Pharmacovigilance: What can we Learn from Epoetins?

By Ebbers Hans C.

Drug Safety, Vol. 34, Iss. 4, 2011-04 ,pp. : 273-287

Adis International

Access to resources Recommend Favorite